<DOC>
	<DOCNO>NCT02645890</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetics profile CKD-397 healthy male volunteer .</brief_summary>
	<brief_title>Study Compare Safety Pharmacokinetics CKD-397</brief_title>
	<detailed_description>A randomized , open-label , oral single dosing , two-way crossover clinical trial evaluate safety pharmacokinetic profile CKD-397 healthy male subject</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>1 . More 19 year Healthy male volunteer 2 . Body weight ≥ 55kg range calculate BMI 17.5 30.5kg/m2 3 . Subject sign informed consent form willingly 1 . Clinically significant disease hematological , nephrological , respiratory , gastrointestinal , urogenital , cardiovascular , psychiatric , neurologic system allergic disease ( except nonsymptom seasonal allergy ) 2 . Gastrointestinal disease ( esophageal achalasia , esophagus stenosis , crohn 's disease ) gastrointestinal surgery ( except appendectomy herniotomy ) 3 . Aspartate aminotransferase , Alanine aminotransferase &gt; 2 X upper limit normal range eGFR calculate MDRD ( Modification diet renal disease ) &lt; 60mL/min/1.73m2 4 . Continuously take excessive alcohol ( &gt; 210g/week ) within 6 month screen 5 . Have receive investigational drug within 3 month prior first dose 6 . Sitting systolic blood pressure ≤ 100mmHg ≥ 150mmHg , sit diastolic blood pressure ≤ 60mmHg ≥ 100mmHg 7 . Subject orthostatic hypotension 8 . The history drug abuse drug abuse show positive urine drug test 9 . Subject take inducer inhibitor drug metabolize enzyme within 30 day 10 . Cigarette ≥ 20 cigarette day recent 3 month Subject stop smoking clinical trial participation 11 . Subject take ethical drug herbal medicine within 2 week overthecounter drug vitamin within 1 week 12 . Whole blood donation within 2 month component blood donation within 1 month blood transfusion within 1 month prior first dose 13 . Subject increase risk due clinical test administration drug severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result . 14 . Subject take form organic nitrate periodically and/or intermittently . 15 . Subject know hereditary degenerative retinal disease include retinitis pigmentosa . 16 . Subject serious history hypersensitivity investigational product ( include Tadalafil Tamsulosin ) medicine ( aspirin , antibiotic ) 17 . Subject lose sight one eye nonarteritic anterior ischemic optic neuropathy ( NAION , nonarteritic anterior ischemic optic neuropathy ) . 18 . Subject genetic problem galactose intolerance , fructose intolerance , lapp lactase deficiency , glucosegalactose malabsorption sucraseisomaltase insufficiency 19 . Subject planned pregnancy clinical trial n't use trustworthy contraception 20 . Subjects able comply guideline describe protocol . 21 . An impossible one participant clinical trial investigator 's decision include laboratory test result another reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Healthy Male Volunteer</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Tadalafil</keyword>
</DOC>